Genetic variation in Mycobacterium tuberculosis isolates from a London outbreak associated with isoniazid resistance

BMC Med. 2016 Aug 16;14(1):117. doi: 10.1186/s12916-016-0659-6.

Abstract

Background: The largest outbreak of isoniazid-resistant (INH-R) Mycobacterium tuberculosis in Western Europe is centred in North London, with over 400 cases diagnosed since 1995. In the current study, we evaluated the genetic variation in a subset of clinical samples from the outbreak with the hypothesis that these isolates have unique biological characteristics that have served to prolong the outbreak.

Methods: Fitness assays, mutation rate estimation, and whole-genome sequencing were performed to test for selective advantage and compensatory mutations.

Results: This detailed analysis of the genetic variation of these INH-R samples suggests that this outbreak consists of successful, closely related, circulating strains with heterogeneous resistance profiles and little or no associated fitness cost or impact on their mutation rate.

Conclusions: Specific deletions and SNPs could be a peculiar feature of these INH-R M. tuberculosis isolates, and could potentially explain their persistence over the years.

Keywords: Fitness; Mutation rate; Mycobacterium tuberculosis; Whole-genome sequencing.

MeSH terms

  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use
  • Disease Outbreaks*
  • Drug Resistance, Bacterial / drug effects
  • Drug Resistance, Bacterial / genetics
  • Europe / epidemiology
  • Genetic Variation / genetics*
  • Humans
  • Isoniazid / pharmacology
  • Isoniazid / therapeutic use*
  • London / epidemiology
  • Microbial Sensitivity Tests / methods
  • Mutation / genetics
  • Mycobacterium tuberculosis / genetics*
  • Mycobacterium tuberculosis / isolation & purification
  • Polymorphism, Single Nucleotide / genetics
  • Tuberculosis / drug therapy
  • Tuberculosis / epidemiology*
  • Tuberculosis / genetics*
  • Tuberculosis, Multidrug-Resistant

Substances

  • Antitubercular Agents
  • Isoniazid